5 research outputs found
Emergence of Anti-Cancer Drug Resistance: Exploring the Importance of the Microenvironmental Niche via a Spatial Model
Practically, all chemotherapeutic agents lead to drug resistance. Clinically,
it is a challenge to determine whether resistance arises prior to, or as a
result of, cancer therapy. Further, a number of different intracellular and
microenvironmental factors have been correlated with the emergence of drug
resistance. With the goal of better understanding drug resistance and its
connection with the tumor microenvironment, we have developed a hybrid
discrete-continuous mathematical model. In this model, cancer cells described
through a particle-spring approach respond to dynamically changing oxygen and
DNA damaging drug concentrations described through partial differential
equations. We thoroughly explored the behavior of our self-calibrated model
under the following common conditions: a fixed layout of the vasculature, an
identical initial configuration of cancer cells, the same mechanism of drug
action, and one mechanism of cellular response to the drug. We considered one
set of simulations in which drug resistance existed prior to the start of
treatment, and another set in which drug resistance is acquired in response to
treatment. This allows us to compare how both kinds of resistance influence the
spatial and temporal dynamics of the developing tumor, and its clonal
diversity. We show that both pre-existing and acquired resistance can give rise
to three biologically distinct parameter regimes: successful tumor eradication,
reduced effectiveness of drug during the course of treatment (resistance), and
complete treatment failure
Targeting BRAFV600E in thyroid carcinoma: Therapeutic implications
B-Raf is an important mediator of cell proliferation and survival signals transduced via the Ras-Raf-MEK-ERK cascade. BRAF mutations have been detected in several tumors, including papillary thyroid carcinoma, but the precise role of B-Raf as a therapeutic target for thyroid carcinoma is still under investigation. We analyzed a panel of 93 specimens and 14 thyroid carcinoma cell lines for the presence of BRAF mutations and activation of the mitogen-activated protein/ERK kinase (MEK)/extracellular signal-regulated kinase (ERK) pathway. We also compared the effect of a B-Raf small inhibitory RNA construct and the B-Raf kinase inhibitor AAL881 on both B-Raf wild-type and mutant thyroid carcinoma cell lines. We found a high prevalence of the T1799A (V600E) mutation in papillary and anaplastic carcinoma specimens and cell lines. There was no difference in patient age, B-Raf expression, Ki67 immunostaining, or clinical stage at presentation between wild-type and BRAFV600E specimens. Immunodetection of phosphorylated and total forms of MEK and ERK revealed no difference in their phosphorylation between wild-type and BRAFV600E patient specimens or cell lines. Furthermore, a small inhibitory RNA construct targeting the expression of both wild-type B-Raf and B-RafV600E induced a comparable reduction of viability in both wild-type and BRAFV600E mutant cancer cells. Interestingly, AAL881 inhibited MEK and ERK phosphorylation and induced apoptosis preferentially in BRAFV600E-harboring cells than wild-type ones, possibly because of better inhibitory activity against B-RafV600E. We conclude that B-Raf is important for the pathophysiology of thyroid carcinomas irrespective of mutational status. Small molecule inhibitors that selectively target B-RafV600E may provide clinical benefit for patients with thyroid cancer. Copyright © 2007 American Association for Cancer Research